首页
内分泌科 神经内科 心血管内科 消化内科 风湿免疫科 血液科 肾内科 呼吸内科 神经外科 心脏外科 胸部外科 普通外科 肝胆外科 烧伤外科 整形外科 泌尿外科 妇产科 儿科 皮肤性病科 感染科 眼科 急诊科 精神科 口腔科 肿瘤科 骨科 耳鼻咽喉头颈外科
疾病 检查 药品 操作 文献 专题 路径 法规 量表

您的账号已在其他设备登录，您当前账号已强迫下线，
如非您本人操作，建议您在会员中心进行密码修改

确定
首页 > GMS health technology assessment > Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (...
Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
LinkOut
收藏 | 浏览109

"Patient-Reported Outcome" (PRO) is used as an umbrella term for different concepts for measuring subjectively perceived health status e. g. as treatment effects. Their common characteristic is, that the appraisal of the health status is reported by the patient himself. In order to describe the informative value of PRO in Health Technology Assessment (HTA) first an overview of concepts, classifications and methods of measurement is given. The overview is complemented by an empirical analysis of clinical trials and HTA-reports on rheumatoid arthritis and breast cancer in order to report on type, frequency and consequences of PRO used in these documents.For both issues systematic reviews of the literature have been performed. The search for methodological literature covers the publication period from 1990 to 2009, the search for clinical trials of rheumatoid arthritis and breast cancer covers the period 2005 to 2009. Both searches were performed in the medical databases of the German Institute of Medical Documentation and Information (DIMDI). The search for HTA-reports and methodological papers of HTA-agencies was performed in the CRD-Databases (CRD = Centre for Reviews and Dissemination) and by handsearching the websites of INAHTA member agencies (INAHTA = International Network of Agencies for Health Technology Assessment). For all issues specific inclusion and exclusion criteria were defined. The methodological quality of randomized controlled trials (RCT) was assessed by a modified version of the Cochrane Risk of Bias Tool. For the methodological part information extraction from the literature is structured by the report's chapters, for the empirical part data extraction sheets were constructed. All information is summarized in a qualitative manner.Concerning the methodological issues the literature search retrieved 158 documents (87 documents related to definition or classification, 125 documents related to operationalisation of PRO). For the empirical analyses 225 RCT (rheumatoid arthritis: 77; breast cancer: 148) and 40 HTA-reports and method papers were found. The analysis of the methodological literature confirms the role of PRO as an umbrella term for a variety of different concepts. The newest classification system facilitates the description of PRO measures by construct, target population and the method of measurement. Steps of operationalisation involve defining a conceptual framework, instrument development, exploration of measurement properties or, possibly, the modification of existing instruments. Seven out of 59 RCT analysing the effects of antibody therapy for rheumatoid arthritis define PRO as the primary endpoint, 38 trials utilize composite measures (ACR, DAS) and ten trials report clinical or radiological parameters as the primary endpoint. Six out of 123 chemotherapy trials for breast cancer define PRO as the primary endpoint, while 98 trials report clinical endpoints (survival, tumour response, progression) in their primary analyses. Discrepancies in the number of trials result from inaccurate specifications of endpoints in the publications. This distribution is reflected in the HTA-reports: while almost all reports on rheumatoid arthritis refer to PRO, this is only the case in about half of the reports on breast cancer.As definition and classification of PRO are concerned, coherent concepts are found in the literature. Their operationalisation and implementation must be guided by scientific principles. The type and frequency of PRO used in clinical trials largely depend on the disease analysed. The HTA-community seems to pursue the utilization of PRO proactively - in case of missing data the need for further research is stated.

作者：Christian, Brettschneider；Dagmar, Lühmann；Heiner, Raspe

来源：GMS health technology assessment 2011 年 7卷

循证病因 循证诊断 循证治疗 系统评价与Meta分析 随机对照研究
知识库介绍

临床诊疗知识库该平台旨在解决临床医护人员在学习、工作中对医学信息的需求，方便快速、便捷的获取实用的医学信息，辅助临床决策参考。该库包含疾病、药品、检查、指南规范、病例文献及循证文献等多种丰富权威的临床资源。

详细介绍
热门关注
免责声明：本知识库提供的有关内容等信息仅供学习参考，不代替医生的诊断和医嘱。

Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
收藏
| 浏览：109
作者：
Christian, Brettschneider；Dagmar, Lühmann；Heiner, Raspe
来源：
GMS health technology assessment 2011 年 7卷
标签：
EBM HTA HTA report HTA-report Health Technology Assessment RCT academic review accident arthritis, rheumatoid biomedical technology assessment blinded blinded study blinded trial blinding breast cancer breast neoplasms carcinoma of the breast care clinical studies clinical trials clinical trials as topic concept controlled clinical study controlled clinical trial controlled clinical trials as topic cost analysis cost control cost effectiveness cost reduction cost-benefit analyses cost-benefit-analyses cost-cutting cost-effectiveness costs costs and cost analysis cross-over procedure cross-over studies cross-over trials crossover procedure decision making diagnosis double blind double blind method double blind procedure double-blind method double-blind procedure doubleblind economic aspect economics economics, medical effectiveness efficacy efficiency endpoint endpoint determination ethics evaluation studies as topic evidence based medicine evidence-based medicine health health economic studies health economics health policy health status humans judgement juridical medical assessment medical costs medical evaluation meta analysis meta analysis as topic meta-analysis methods models, economic multicenter studies multicenter studies as topic multicenter trial multicenter trials patient report patient reported outcome patient satisfaction patient statement patient-relevant patient-relevant endpoint patient-reported outcome patients peer review pharmacoeconomics placebo placebo effect placebos prevention prospective studies quality of life random random allocation randomisation randomised clinical study randomised clinical trial randomised controlled study randomised controlled trial randomised study randomised trial randomization randomized clinical study randomized clinical trial randomized controlled study randomized controlled trial randomized controlled trials as topic randomized study randomized trial rehabilitation report research article research-article review review literature review literature as topic rheumatoid arthritis rights risk assessment sensitivity sickness costs single blind single blind method single blind procedure single-blind single-blind method single-blind procedure social economic factors socioeconomic factors socioeconomics specifity systematic review technical report technology technology assessment technology assessment, biomedical technology evaluation technology, medical therapy treatment trial, cross-over trial, crossover triple blind triple blind method triple blind procedure triple-blind procedure tripleblind tripleblind method validation studies validation studies as topic
"Patient-Reported Outcome" (PRO) is used as an umbrella term for different concepts for measuring subjectively perceived health status e. g. as treatment effects. Their common characteristic is, that the appraisal of the health status is reported by the patient himself. In order to describe the informative value of PRO in Health Technology Assessment (HTA) first an overview of concepts, classifications and methods of measurement is given. The overview is complemented by an empirical analysis of clinical trials and HTA-reports on rheumatoid arthritis and breast cancer in order to report on type, frequency and consequences of PRO used in these documents.For both issues systematic reviews of the literature have been performed. The search for methodological literature covers the publication period from 1990 to 2009, the search for clinical trials of rheumatoid arthritis and breast cancer covers the period 2005 to 2009. Both searches were performed in the medical databases of the German Institute of Medical Documentation and Information (DIMDI). The search for HTA-reports and methodological papers of HTA-agencies was performed in the CRD-Databases (CRD = Centre for Reviews and Dissemination) and by handsearching the websites of INAHTA member agencies (INAHTA = International Network of Agencies for Health Technology Assessment). For all issues specific inclusion and exclusion criteria were defined. The methodological quality of randomized controlled trials (RCT) was assessed by a modified version of the Cochrane Risk of Bias Tool. For the methodological part information extraction from the literature is structured by the report's chapters, for the empirical part data extraction sheets were constructed. All information is summarized in a qualitative manner.Concerning the methodological issues the literature search retrieved 158 documents (87 documents related to definition or classification, 125 documents related to operationalisation of PRO). For the empirical analyses 225 RCT (rheumatoid arthritis: 77; breast cancer: 148) and 40 HTA-reports and method papers were found. The analysis of the methodological literature confirms the role of PRO as an umbrella term for a variety of different concepts. The newest classification system facilitates the description of PRO measures by construct, target population and the method of measurement. Steps of operationalisation involve defining a conceptual framework, instrument development, exploration of measurement properties or, possibly, the modification of existing instruments. Seven out of 59 RCT analysing the effects of antibody therapy for rheumatoid arthritis define PRO as the primary endpoint, 38 trials utilize composite measures (ACR, DAS) and ten trials report clinical or radiological parameters as the primary endpoint. Six out of 123 chemotherapy trials for breast cancer define PRO as the primary endpoint, while 98 trials report clinical endpoints (survival, tumour response, progression) in their primary analyses. Discrepancies in the number of trials result from inaccurate specifications of endpoints in the publications. This distribution is reflected in the HTA-reports: while almost all reports on rheumatoid arthritis refer to PRO, this is only the case in about half of the reports on breast cancer.As definition and classification of PRO are concerned, coherent concepts are found in the literature. Their operationalisation and implementation must be guided by scientific principles. The type and frequency of PRO used in clinical trials largely depend on the disease analysed. The HTA-community seems to pursue the utilization of PRO proactively - in case of missing data the need for further research is stated.

关于我们 产品特色 专家团队

免责声明：本知识库提供的有关疾病、症状、检查、药品、指南规范、循证文献和病例文献等信息仅供医生学习参考。

2015 北京万方数据股份有限公司 互联网药品信息服务资格证书号：(京)-经营性-2011-0017 京ICP证010071号